Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
Clinical Journal of the American Society of Nephrology · 2026
DOI: 10.2215/cjn.0000000961 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Hiddo J L Heerspink und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Proteinuria, Glomerulonephritis, IGA, Kidney, Irbesartan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Travere Therapeutics, Inc..
Abstract (Originalsprache)
Key Points This analysis explored the association between complete remission of proteinuria and kidney function decline during sparsentan or irbesartan treatment. Patients achieving complete remission of proteinuria experienced better eGFR preservation and fewer kidney failure events. These data support Kidney Disease Improving Global Outcomes guideline recommendations to maintain proteinuria levels in IgA nephropathy ideally below 0.3 g/d.
Background
In the phase 3, randomized, double-blind PROTECT (NCT03762850) trial, sparsentan, a single-molecule dual endothelin angiotensin receptor antagonist, reduced proteinuria and preserved kidney function compared with maximum labeled dose irbesartan in adults with IgA nephropathy. In this post hoc analysis of PROTECT, we assessed the association between complete remission of proteinuria (CR) and preservation of kidney function.
Methods
This analysis compared kidney function in patients who achieved CR (urine protein excretion
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands.
- University Wexner Medical Center, Columbus, Ohio.
- Travere Therapeutics, Inc., San Diego, California.
- JAMCO Pharma Consulting, Stockholm, Sweden.
- General University Hospital, Charles University, Prague, Czech Republic.
ORCID-Profile: Hiddo J L Heerspink, Brad H Rovin, Radko Komers, Bruce Hendry, Alex Mercer, Priscila Preciado, Vladimir Tesar
Förderung
- Travere Therapeutics, Inc.
Zitieren
APA
Heerspink, H. J. L., Rovin, B. H., Komers, R., Hendry, B., Mercer, A., Preciado, P., Murphy, E., & Tesar, V. (2026). Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000000961
Vancouver
Heerspink HJL, Rovin BH, Komers R, Hendry B, Mercer A, Preciado P, et al. Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000000961
BibTeX
@article{Heerspink2026,
author = {Heerspink, Hiddo J L and Rovin, Brad H and Komers, Radko and Hendry, Bruce and Mercer, Alex and Preciado, Priscila and Murphy, Edward and Tesar, Vladimir},
title = {Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000000961}
}
EUVIMED